Skip to main content

Advertisement

SpringerLink
Log in

The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

This study aimed to investigate immunohistochemical staining of sodium iodide symporter (NIS) and its effect on response to I-131 therapy in differentiated thyroid carcinoma patients.

Methods

We evaluated NIS expression, the intracellular distribution of NIS, iodine-131 uptake in residual tissues on post-ablation I-131 whole body scan, and the ablation status after 100 mCi I-131 therapy. We also investigated NIS expression and localization in tumoral paraffin-embedded tissues.

Results

In this retrospective study, 35 patients (mean age 44.17 ± 12.9 years, 27 female, 8 male) were studied. Twenty-one of these patients responded to radioiodine therapy, and 14 did not. NIS expression and iodine-131 uptake in residual tissues post-ablation I-131 whole body scan were not statistically significant. When we compared the patients who responded to radioiodine therapy and the poor responder group, NIS expression and iodine-131 uptake in residual tissues did not demonstrate statistically significant difference [(p = 0.308) (p = 0.985) respectively]. 47.6% of the patients in the successful ablation group and 85.7% in the unsuccessful ablation group had intracellular NIS immunostaining. The difference was not statistically significant (p = 0.139). 52.4% of the patients in the successful ablation group and 7% in the unsuccessful ablation group had NIS immunostaining at the basolateral membrane. The difference was statistically significant (p < 0.05).

Conclusions

In conclusion, we did not find any significant difference between successful and unsuccessful ablation groups in terms of NIS expression; however, we concluded that the intracellular (cytoplasmic) localization of NIS is one of the leading causes of ablation failure regardless of NIS expression in DTC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  PubMed  Google Scholar 

  2. Weetman AP, Jameson JL. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Disorders of the thyroid gland Harrison’s Principles of Internal Medicine. 15th ed. New York: The McGraw Hill Companies; 2001. p. 2060–84.

    Google Scholar 

  3. Hussain HK, Britton KE, Grossman AB, Reznek RH. In: Husband JE, Reznek RH, editors. Thyroid cancer. Imaging in Oncology. 2nd ed. London: Taylor and Francis; 2004. p. 669–709.

    Google Scholar 

  4. Amdur RJ, Mazzaferri EL. İncidence, prevalence, recurrence, and mortality of differentiated thyroid cancer. In: Amdur RJ, Mazzaferri EL, editors. Essentials of Thyroid Cancer Management. New York: Springer Science; 2005. p. 123–30.

    Chapter  Google Scholar 

  5. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol. 2002;57:559–74.

    Article  CAS  Google Scholar 

  6. Mazzaferri EL, Amdur RJ. Thyroid and parathyroid physiology. In: Amdur RJ, Mazzaferri EL, editors. Essentials of Thyroid Cancer Management. New York: Springer Science; 2005. p. 7–17.

    Chapter  Google Scholar 

  7. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab. 1998;83:4102–6.

    CAS  PubMed  Google Scholar 

  8. Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol. 2009;160:215–25.

    Article  CAS  PubMed  Google Scholar 

  9. Shen DH, Kloos RT, Mazzaferri EL, Jhiang SM. Sodium iodide symporter in health and disease. Thyroid. 2001;11:415–25.

    Article  CAS  PubMed  Google Scholar 

  10. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–57.

    Article  CAS  PubMed  Google Scholar 

  11. Jhiang SM, Sipos JA. Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy. Endocr Relat Cancer. 2021;28(10):T167–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.

    Article  CAS  PubMed  Google Scholar 

  13. Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targetting for cancer therapeutics. Pharmacol Ther. 2012;135:355–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cai X, Wang R, Tan J, Meng Z, Li N. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer. Clin Transl Oncol. 2021;23(12):2403–14.

    Article  CAS  PubMed  Google Scholar 

  15. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639–45.

    Article  CAS  PubMed  Google Scholar 

  16. Morari EC, Marcello MA, Guilhen ACT, Cunha LL, Latuff P, Soares FA, et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol. 2011;75:247–54.

    Article  CAS  Google Scholar 

  17. Ward LS, Santarosa PL, Granja F, Assumpção LVM, Savoldi M, Goldman GH. Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett. 2003;200:85–91.

    Article  CAS  PubMed  Google Scholar 

  18. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab. 2001;86(11):5627–32.

    Article  CAS  PubMed  Google Scholar 

  19. Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer. 2020;27(5):R113–32.

    Article  PubMed  Google Scholar 

  20. Sodré AKMB, Rubio IGS, Galrão ALR, Knobel M, Tomimori EK, Alves VAF, et al. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab. 2008;93:4141–5.

    Article  PubMed  Google Scholar 

  21. Dohan O, Carrasco N. Advances in Na+/I− symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol. 2003;213:59–70.

    Article  CAS  PubMed  Google Scholar 

  22. Dohán O, Baloch Z, Bánrévi Z, Livolsi V, Carrasco N. Predominant intracellular overexpression of the Na+/I- Symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001;86(6):2697–700.

    PubMed  Google Scholar 

  23. Kogai T, Endo T, Saito T, Miyazakia A, Kawaguchia A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology. 1997;138:2227–32.

    Article  CAS  PubMed  Google Scholar 

  24. Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem. 2001;276(24):21458–63.

    Article  CAS  PubMed  Google Scholar 

  25. Anekpuritanang T, Uataya M, Claimon A, Laokulrath N, Pongsapich W, Pithuksurachai P. The association between radioiodine refractory in papillary thyroid carcinoma, sodium/iodide symporter expression, and BRAFV600E mutation. Onco Targets Ther. 2021;14:3959–69.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52(6):765–73.

    Article  CAS  Google Scholar 

  27. Smith VE, Sharma N, Watkins RJ, Read ML, Ryan GA, Kwan PP, et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab. 2013;98(7):2876–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhao Z, Huang R, Cai H, Liu B, Zeng Y, Kuang A. Improved radioiodine-131 imaging of prostatic carcinoma using the sodium iodide symporter gene under control of the survivin promoter. Int J Clin Exp Pathol. 2018;11(8):4067–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Son SH, Gangadaran P, Ahn BC. A novel strategy of transferring NIS protein to cells using extracellular vesicles leads to increase in iodine uptake and cytotoxicity. Int J Nanomedicine. 2019;14:1779–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, et al. Reintroducing the sodium-iodide symporter to anaplastic thyroid carcinoma. Thyroid. 2017;27(12):1534–43.

    Article  CAS  PubMed  Google Scholar 

  31. Spitzweg C, Nelson PJ, Wagner E, Bartenstein P, Weber WA, Schwaiger M, et al. The sodium iodide symporter (NIS) novel applications for radionuclide imaging and treatment. Endocr Relat Cancer. 2021;28:193–213.

    Article  Google Scholar 

Download references

Funding

The authors declared that this study has received no financial support.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, School of Medicine, Manisa Celal Bayar University, Uncubozkoy, 45030, Manisa, Turkey

    Gozde mutevelızade

  2. Department of Nuclear Medicine, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkey

    Nazım Emrah Kocer

  3. Department of Pathology, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkey

    Mehmet Reyhan

Authors
  1. Gozde mutevelızade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nazım Emrah Kocer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Reyhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gozde mutevelızade.

Ethics declarations

Conflict of Interest

The authors have no conflicts of interest to declare.

Informed Consent

Written informed consent was obtained from the patients who participated in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

mutevelızade, G., Kocer, N.E. & Reyhan, M. The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer. Ann Nucl Med 36, 1050–1058 (2022). https://doi.org/10.1007/s12149-022-01794-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-022-01794-w

Keywords

Search

Navigation